- The overactive bladder (OAB) treatment market includes a range of pharmacological therapies, neuromodulation devices, and behavioral interventions aimed at managing symptoms such as urgency, frequency, and urge incontinence. These treatments are critical for improving patient quality of life
- The demand for OAB treatments is significantly driven by the growing elderly population, rising awareness of urinary disorders, and increased diagnosis rates. A large portion of global demand stems from women over the age of 40, who are disproportionately affected by overactive bladder
- North America stands out as one of the dominant regions for OAB treatments, supported by its advanced healthcare infrastructure, early adoption of novel therapies, and strong presence of key pharmaceutical companies
- For instance, the U.S. has seen an increase in prescriptions for antimuscarinic and beta-3 adrenergic agonist drugs, driven by awareness campaigns and proactive urological health screenings, especially among aging adults
- Globally, pharmacological treatments remain the primary method of managing OAB, but there is growing adoption of neuromodulation therapies and combination treatments, reflecting a shift toward more personalized and effective long-term management solutions
